A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
- Intervention
- Procedure: Contrast-enhanced Magnetic Resonance Imaging · Biological: Ipilimumab · Biological: Nivolumab · Device: NovoTTF-100A Device · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Temozolomide